The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

AMPHETAMINE (BENZEDRINE) SULFATE AS A CORRECTIVE FOR THE DEPRESSION OF SEDATIVE MEDICATION IN EPILEPSY

Published Online:https://doi.org/10.1176/ajp.98.2.215

Amphetamine ( benzedrine) sulfate, (5-30 mgm.) was given to 58 epileptic patients with toxic manifestations as a result of increased anti-convulsant medication, the latter consisting mainly or in part of phenobarbital in all but one case, (receiving mebaral alone).

The toxic effects of the anti-convulsant medication consisted of drowsiness, ataxia, irritability, aggressiveness, anorexia, vertigo, nystagmus and tremor.

Amphetamine (benzedrine) sulfate was notably of value in combating the drowsiness (64.2 per cent of cases); and secondarily of value in relieving ataxia, irritability, aggressiveness and anorexia, associated with the drowsiness.

Amphetamine was effective in 39 cases, ineffective in 18 cases. When effective, amphetamine was constantly necessary in 18 patients, and only temporarily necessary (7 days to 2 months) in 21 patients.

In itself, amphetamine (benzedrine) sulfate did not affect the incidence of epileptic seizures.

By counteracting toxic effects amphetamine (benzedrine) sulfate made it possible, in many cases, to reduce seizures by giving adequate anti-convulsant medication, and in this respect proved of appreciable importance as an adjunct in the therapy of epilepsy.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.